Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK

Georgia Hollier-Hann,Alistair Curry,Kateryna Onishchenko,Ron Akehurst,Fayyaz Ahmed,Brendan Davies,Ian Keyzor

Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK

2019

Georgia Hollier-Hann
Alistair Curry
Kateryna Onishchenko
Ron Akehurst
Fayyaz Ahmed
Brendan Davies
Ian Keyzor

AbstractAims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA fo...

Keywords:

Chronic Migraine
Nice
Intensive care medicine
Cost-effectiveness analysis
Physical therapy
Economic evaluation
Medicine
onabotulinumtoxin a
cost effectiveness

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations